- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02463682
Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting
Early Feasibility Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAS) in the Outpatient Setting
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Santa Barbara, California, United States, 93111
- William Sansum Diabetes Center
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one year and using insulin for at least 1 year and an insulin pump for at least 6 months
- Willing to wear the study CGM device for the duration of the study
- Age ≥21 to <65 years
- HbA1c <10.0%; if HbA1c <6.0% then total daily insulin must be ≥0.5 U/kg
- For females, not currently known to be pregnant If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study. A negative urine pregnancy test will be required for all premenopausal women who are not surgically sterile. Subjects who become pregnant will be discontinued from the study.
- Demonstration of proper mental status and cognition for the study
- Currently using insulin-to-carbohydrate ratio to calculate meal bolus sizes
- Hypoglycemia awareness as demonstrated by a Clarke Hypoglycemia Unawareness score of 2 or lower
- Access to internet and cell phone service at home, and a computer for downloading device data
- Availability of care partner committed to participating in training activities, knowledgeable at all times of the participant's location, and being present and available to provide assistance when system is being used at night
- Commitment to maintaining uninterrupted availability via cell phone and avoiding any overnight travel for the duration the period using the closed-loop system
- An understanding of and willingness to follow the protocol and sign the informed consent
Exclusion Criteria:
- Admission for diabetic ketoacidosis in the 12 months prior to enrollment
- Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment
- History of a seizure disorder (except hypoglycemic seizure), unless written clearance is received from a neurologist
- Coronary artery disease or heart failure, unless written clearance is received from a cardiologist
- History of cardiac arrhythmia (except for benign premature atrial contractions and benign premature ventricular contractions which are permitted)
- Cystic fibrosis
A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol such as the following examples:
- Inpatient psychiatric treatment in the past 6 months for either the subject or the subject's primary care giver (i.e., parent or guardian)
- Presence of a known adrenal disorder
- Abnormal liver function test results (Transaminase >2 times the upper limit of normal); testing required for subjects taking medications known to affect liver function or with diseases known to affect liver function
- Abnormal renal function test results (calculated GFR <60 mL/min/1.73m2); testing required for subjects with diabetes duration of greater than 5 years post onset of puberty
- Active gastroparesis
- If on antihypertensive, thyroid, anti-depressant or lipid lowering medication, lack of stability on the medication for the past 2 months prior to enrollment in the study
- Uncontrolled thyroid disease (TSH undetectable or >10 mlU/L); testing required within three months prior to admission for subjects with a goiter or who are on thyroid hormone replacement, and within one year otherwise
- Abuse of alcohol or recreational drugs
- Infectious process not anticipated to resolve prior to study procedures (e.g. meningitis, pneumonia, osteomyelitis)
- A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol
Current use of the following drugs and supplements:
- Acetaminophen
- Any medication being taken to lower blood glucose, such as Pramlintide, Metformin,GLP-1 Analogs such as Liraglutide, and nutraceuticals intended to lower blood glucose
- Beta blockers
- Oral or injectable glucocorticoids
- Any other medication that the investigator believes is a contraindication to the subject's participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sensor-Augmented Pump Open-Loop Care (Week 1)
The subjects Sensor-Augmented Pump Open-Loop Care for the first week of the study before any adjustments to pump settings.
|
Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
|
Experimental: Closed-Loop Control System with Zone MPC and HMS
The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
The Health Monitoring System algorithm uses the same CGM data as the MPC control algorithm but utilizes a separate algorithm for trending and predictions of future glucose values.
Using a redundant and independent algorithm is an important safety feature of the overall AP device.
|
The devices that will be used in the Closed-Loop Control System include the following components: DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS) |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and efficacy of the system, as assessed by the composite outcome of time in range for glucose levels of 70-180 mg/dL and time < 70 mg/dL.
Time Frame: 1 Week
|
The primary endpoint for this pilot study will be to determine the safety and efficacy of the system, as assessed by the composite outcome of time in range for glucose levels of 70-180 mg/dL and time < 70 mg/dL, comparing between sensor-augmented pump use (open loop care) (week 1) to closed-loop care (final week), so as to determine the feasibility of eventual long-term use of the system.
|
1 Week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time in range for glucose 80-140 mg/dL
Time Frame: 1 Week
|
Time in range for glucose 80-140 mg/dL at all times unless described otherwise.
|
1 Week
|
Time in range for glucose during the nocturnal period
Time Frame: 1 week
|
Time in range for glucose 70-180 mg/dL during the nocturnal period.
|
1 week
|
Time in Range Postprandial
Time Frame: 1 Week
|
Time in range for glucose 70-180 mg/dL postprandial, for 5 hours following all meals
|
1 Week
|
Markers of hypo- and hyperglycemia
Time Frame: 1 Week
|
Markers of hypo- and hyperglycemia.
|
1 Week
|
Insulin Doses Given
Time Frame: 1 Week
|
Change in insulin doses given between the open and closed-loop phases of the study.
|
1 Week
|
Treatments for hypoglycemia
Time Frame: 1 week
|
Treatments for hypoglycemia between the open and closed-loop phases of the study.
|
1 week
|
Number of alerts given by the HMS to prevent hypoglycemia
Time Frame: 2 Weeks
|
Number of alerts given by the HMS to prevent hypoglycemia during closed-Loop control.
|
2 Weeks
|
Outside interventions needed
Time Frame: 2 Weeks
|
Outside interventions needed to aid with treatment during closed-Loop control.
|
2 Weeks
|
Failure analysis of the devices/connectivity issues that may occur.
Time Frame: 2 Weeks
|
Failure analysis of the devices/connectivity issues that may occur during closed-Loop control.
|
2 Weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Francis J Doyle III, PhD, University of California, Santa Barbara/William Sansum Diabetes Center
- Principal Investigator: Eyal Dassau, PhD, University of California, Santa Barbara/William Sansum Diabetes Center
- Principal Investigator: Ananda Basu, MD, Mayo Clinic, Rochester, MN
- Principal Investigator: Yogish Kudva, MD, Mayo Clinic, Rochester, MN
- Principal Investigator: Boris Kovatchev, PhD, University of Virginia
- Principal Investigator: Stephen Patek, PhD, University of Virginia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 99796-JPIN
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on CGM and Insulin Pump
-
Centre Hospitalier du LuxembourgCompletedDiabetes Mellitus, Type 1Luxembourg
-
Steen AndersenMedtronicCompletedType 1 Diabetes MellitusDenmark
-
University of CambridgeNorfolk and Norwich University Hospitals NHS Foundation Trust; Barts & The... and other collaboratorsRecruiting
-
Imperial College LondonLondon Ambulance ServiceTerminatedHypoglycemia | Diabetes Mellitus, Type 1 | Hypoglycemia UnawarenessUnited Kingdom
-
University of CambridgeCambridge University Hospitals NHS Foundation TrustCompleted
-
Sue BrownDexCom, Inc.; Roche DiagnosticsTerminatedType 1 Diabetes MellitusUnited States
-
Tandem Diabetes Care, Inc.Jaeb Center for Health ResearchRecruitingType 2 Diabetes Treated With InsulinUnited States, Canada
-
Sansum Diabetes Research InstituteMayo Clinic; University of Padova; University of Virginia; Harvard University; University...Completed
-
Massachusetts General HospitalBoston UniversityCompletedDiabetes Mellitus Type 1United States
-
Children's Hospital of Eastern OntarioJuvenile Diabetes Research Foundation; Canadian Clinical Trial NetworkCompleted